Full Breakdown
NICE Recommends Fezolinetant for Menopausal Symptoms
3/13/2026, 10:57:44 AM
Introduction of a New Treatment Option
The National Institute for Health and Care Excellence (NICE) has recommended Fezolinetant, also known as Veoza, as the first non-hormonal treatment for menopausal hot flushes and night sweats to be routinely used within the National Health Service (NHS). This recommendation addresses a significant need for women who cannot or prefer not to take hormone replacement therapy (HRT). Fezolinetant, manufactured by Astellas Pharma, is a 45mg tablet taken once daily that works by blocking nerve pathways in the brain that trigger these symptoms.
Background and Context
Historically, treatment options for menopausal symptoms have been limited for women with contraindications to HRT, such as those with a history of deep vein thrombosis or pulmonary embolism. NICE's decision comes after patient testimonies highlighted the profound impact of menopausal symptoms on quality of life, including sleep disturbances, fatigue, and emotional distress. Approximately 500,000 women in England are estimated to potentially benefit from this new treatment.
Clinical Evidence and Effectiveness
NICE's recommendation is based on evidence from three multicenter randomized trials: DAYLIGHT, SKYLIGHT 1, and SKYLIGHT 2. These studies demonstrated that Fezolinetant effectively reduces the frequency and severity of vasomotor symptoms compared to placebo. Although there is some uncertainty regarding the exact magnitude of the benefits due to statistical methods used in the trials, the cost-effectiveness ratios were deemed acceptable for NHS resources.
Official Statements & Responses
Helen Knight, director of medicines evaluation at NICE, emphasized the importance of this treatment option, stating, “We know that menopausal hot flushes and night sweats can have a profound impact on quality of life and significantly affect overall wellbeing.” Dr. Sue Mann, national clinical director in Women’s Health for NHS England, noted that Fezolinetant could help hundreds of thousands of women manage their menopause symptoms more effectively.
Criticism & Opposition
Despite the positive reception, there are concerns regarding the safety profile of Fezolinetant. The most common side effects include abdominal pain, diarrhea, insomnia, back pain, and, paradoxically, hot flushes. NICE has also indicated that the drug is not recommended for women with current breast cancer or other estrogen-dependent cancers, and there is limited evidence for its use in women who have previously completed treatment for such conditions.
What's Next
As Fezolinetant becomes available on the NHS, ongoing monitoring of its safety and effectiveness will be crucial. Regular liver function tests are recommended due to the potential for hepatotoxicity associated with the drug. The healthcare community will be observing how this new treatment option impacts the management of menopausal symptoms among women who are unable to use HRT.
Verbatim Quotes
- “‘The evidence shows fezolinetant can meaningfully reduce symptoms, and was found to be cost-effective, offering value for the taxpayer.” — Helen Knight, Director of Medicines Evaluation at NICE
- “It’s another vital treatment option which could help hundreds of thousands of women experiencing menopause to better manage their symptoms and feel more in control of their health,” — Dr. Sue Mann, National Clinical Director in Women’s Health for NHS England.
